Posted 27 days ago
Associate Director of Regulatory Affairs - Cell Therapy
@ Immix Biopharma (Nasdaq: IMMX)
Toronto, Ontario
Overview
Immix Biopharma is hiring an Associate Director of Regulatory Affairs for Cell Therapy in Toronto, hybrid. The role supports regulatory strategy and execution for clinical trials under FDA, EMA and other agency rules, including preparing and submitting INDs and maintaining regulatory records. The posting states full-time employment and a hybrid arrangement but no pay or office days.
Responsibilities:
- Prepare, review and submit INDs and regulatory filings
- Monitor regulatory changes and communicate updates
- Coordinate documentation with internal and external partners
- Maintain regulatory correspondence and submission records
- Support regulatory audits and inspections
Requirements summary:
- Bachelor's degree in life sciences, pharmacy or related field
- 3-5 years regulatory affairs in biopharma
- Knowledge of FDA, EMA, Health Canada and MHRA requirements
- Strong written and verbal communication
- Excellent organizational and project management skills
- Familiarity with eCTD and regulatory software (preferred)
Tools & skills
Source and dates
Source type not verified · apify-linkedin
- Employer posting date
- 2026-10-20
- First seen by our source
- 2026-11-14
- Source record updated
- 2026-11-14
These dates describe the source record, not a live verification that the employer is still hiring. Check the original posting.
Job details
| Seniority | Mid level |
| Department | Quality assurance |
| Experience | 3+ years |
| Hours per week | 40 (estimated) |
| Work setting | Office |
| Position | Mostly sitting |
| Physical demands | physical low · computer high |
| Languages | English |
| Education | Bachelor’s degree (required), Master’s degree (preferred) |
| Fields of study | life sciences, pharmacy |
Summary and details written by AI from the posting; the employer’s posting is the authority.
Immix Biopharma (Nasdaq: IMMX)
| Field | Value |
|---|---|
| Open jobs on Jobsy | 2 |
Immix Biopharma, Inc.
Toronto / Hybrid
Associate Director of Regulatory Affairs - Cell Therapy
Our 3 Core Values
- Intelligence
- Integrity
- Initiative
What You’ll Do
The Associate Director of Regulatory Affairs will support the regulatory strategy and execution for clinical trials conducted under FDA/EMA/Other Regulatory agencies regulations. This role is responsible for preparing, submitting, and maintaining regulatory documents and ensuring compliance with all applicable laws and guidelines. The ideal candidate will demonstrate strong attention to detail, analytical skills, and knowledge of FDA/EMA/HealthCanada/MHRA requirements for investigational products.
Key Responsibilities
- Assist in the preparation, review, and submission of INDs, amendments, and other regulatory filings.
- Monitor regulatory changes and communicate updates to relevant teams to ensure ongoing compliance.
- Coordinate with internal departments and external partners to gather necessary documentation for regulatory submissions.
- Maintain accurate records of regulatory correspondence and submissions.
- Support audits and inspections by regulatory authorities.
Qualifications
- Bachelor’s degree in life sciences, pharmacy, or a related field; advanced degree preferred.
- 3-5 years of experience in regulatory affairs within the biopharmaceutical industry.
- Familiarity with FDA/EMA/HealthCanada/MHRA regulations, clinical trial processes, and regulatory submission requirements.
- Strong written and verbal communication skills.
- Excellent organizational and project management abilities.
Preferred Skills
- Familiarity with eCTD submissions and regulatory software tools.
- Ability to work effectively in a collaborative, fast-paced environment.
- Attention to detail and analytical problem-solving skills.
If you are passionate about supporting innovative biopharmaceutical development and ensuring regulatory compliance, we invite you to apply for this exciting opportunity.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Journal
Only you can see this. Kept on this device, and in your account when you sign in.